Mitochondrial DNA from senescent immune cells activates cGAS‑STING in distant tissues, propagating senescence independently of cytokine SASP
Hypothesis
Senescent immune cells release mitochondrial DNA (mtDNA) via extracellular vesicles that acts as a damage‑associated molecular pattern, triggering the cGAS‑STING pathway in parenchymal cells and inducing senescence without relying on classical SASP cytokines.
Mechanistic Rationale
Aged immune cells accumulate dysfunctional mitochondria that leak mtDNA into the cytosol 4. When these cells become senescent, they increase shedding of microvesicles enriched for oxidized mtDNA 3. Circulating vesicles deliver mtDNA to non‑immune tissues where cytosolic cGAS senses DNA, producing STING‑dependent IFN‑β and downstream NF‑κB activation. This pathway can upregulate p21^cip1^ and p16^ink4a^, establishing a senescent state even when IL‑6, IL‑1β, or TGF‑β are neutralized.
Testable Predictions
- Vesicle transfer – Isolated vesicles from senescent old mouse CD8^+^ T cells will induce p21 expression in young hepatocytes in vitro; this effect will be abrogated by DNase I treatment of vesicles or by cGAS knockout in target cells.
- In vivo blockade – Administration of a STING inhibitor (e.g., H-151) to aged mice will reduce mtDNA‑induced IFN‑β signatures in liver and kidney and lower senescence markers (SA‑β‑gal, p16) despite persistent SASP cytokine levels.
- Genetic proof – Mice with T‑cell‑specific knockout of mtDNA packaging protein TFAM will show decreased circulating mtDNA‑containing vesicles, attenuated paracrine senescence in peripheral organs, and extended healthspan compared with littermate controls.
- Rescue experiment – Injecting synthetic mtDNA‑laden vesicles into young wild‑type mice will recapitulate multi‑organ senescence and shorten lifespan, an effect lost in STING‑deficient recipients.
Experimental Design
- In vitro: Co‑culture bone‑marrow‑derived senescent T cells (induced via etoposide) with primary hepatocytes; measure vesicle uptake (PKH67 label), cGAS activation (phospho‑TBK1), and senescence (SA‑β‑gal, EdU exclusion). Include controls with RNase, DNase, cycloheximide, and STING siRNA.
- In vivo: Use ER‑CC1 progeroid mice or naturally aged C57BL/6; treat subgroups with H‑151, anti‑CD8 antibody to deplete T cells, or vehicle. Quantify circulating mtDNA (qPCR for mt‑ND1), vesicle numbers (NTA), tissue IFN‑β (ELISA), and senescence burden.
- Genetic: Cross Cd4‑Cre^+^ TFAM^fl/fl^ mice with p16‑3MR reporter line; longitudinally monitor bioluminescent senescence signal, frailty index, and survival.
Potential Confounders and Mitigation
- Off‑target DNA: Ensure vesicle preparations are free of genomic DNA by using DNAse‑resistant protection assays and verifying size exclusion (<200 nm).
- Compensatory pathways: Simultaneously neutralize SASP cytokines (tocilizumab, anakinra) to isolate mtDNA effects.
- Cell‑type specificity: Repeat key experiments with macrophage‑ and NK‑cell‑derived vesicles to confirm T‑cell relevance.
If mtDNA from senescent immune cells drives aging via cGAS‑STING, then targeting this axis—either by preventing vesicle release, degrading extracellular mtDNA, or inhibiting STING—should decouple immune senescence from tissue decay and delay systemic aging, offering a mechanistic refinement beyond cytokine‑centric models.